- Home
- SCNX vs IGC Comparison
SCNX vs IGC Comparison
Compare SCNX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- IGC
- Stock Information
- Founded
- SCNX 2010
- IGC 2005
- Country
- SCNX United States
- IGC United States
- Employees
- SCNX N/A
- IGC N/A
- Industry
- SCNX Other Pharmaceuticals
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- IGC Health Care
- Exchange
- SCNX Nasdaq
- IGC Nasdaq
- Market Cap
- SCNX 33.6M
- IGC 29.4M
- IPO Year
- SCNX 2020
- IGC N/A
- Fundamental
- Price
- SCNX $3.45
- IGC $0.31
- Analyst Decision
- SCNX
- IGC Strong Buy
- Analyst Count
- SCNX 0
- IGC 2
- Target Price
- SCNX N/A
- IGC $3.75
- AVG Volume (30 Days)
- SCNX 10.8K
- IGC 367.3K
- Earning Date
- SCNX 02-18-2025
- IGC 02-18-2025
- Dividend Yield
- SCNX N/A
- IGC N/A
- EPS Growth
- SCNX N/A
- IGC N/A
- EPS
- SCNX 3.55
- IGC N/A
- Revenue
- SCNX N/A
- IGC $1,183,000.00
- Revenue This Year
- SCNX $1,085.75
- IGC N/A
- Revenue Next Year
- SCNX N/A
- IGC $13.38
- P/E Ratio
- SCNX $1.50
- IGC N/A
- Revenue Growth
- SCNX 166.67
- IGC N/A
- 52 Week Low
- SCNX $3.07
- IGC $0.27
- 52 Week High
- SCNX $44.56
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- IGC 35.18
- Support Level
- SCNX N/A
- IGC $0.31
- Resistance Level
- SCNX N/A
- IGC $0.33
- Average True Range (ATR)
- SCNX 0.00
- IGC 0.02
- MACD
- SCNX 0.00
- IGC -0.00
- Stochastic Oscillator
- SCNX 0.00
- IGC 3.89
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.